News & Updates

Show Multimedia Only
Sotrovimab benefits select hospitalized COVID-19 patients
Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026 byStephen Padilla

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.

Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026